Key Highlights

  • Third-quarter 2026 net loss was USD 3.0 million, or USD 0.05 per share.
  • Research and development expenses were USD 2.1 million, against USD 3.3 million.
  • The FDA granted Breakthrough Designation for Heart Attack Assessment in October 2026.
  • Cash and cash equivalents were approximately USD 6.1 million at September 30, 2026.

HeartBeam (NASDAQ:BEAT) reported a third-quarter 2026 net loss of USD 3.0 million, or USD 0.05 per share, against an estimate of a loss of USD 0.09 per share, in its Quarterly Report on Form 10-Q. The Santa Clara, California-based medical technology company states that its HeartBeam System did not generate any Revenue in the three and nine months ended September 30, 2026 or 2025.

Quarterly Results

Research and development expenses were USD 2.1 million, against USD 3.3 million a year earlier, a decrease of approximately USD 1.2 million, or 35%. Selling, general and administrative expenses were USD 1.3 million, against USD 2.0 million. Total operating expenses were USD 3.5 million, against USD 5.3 million, and the loss from operations was USD 3.5 million, against USD 5.3 million.

Total other income was USD 0.4 million, against USD 35 thousand, including other income, net, of USD 384 thousand. Net loss was USD 3.0 million, against USD 5.3 million, and net loss per share was USD 0.05, against USD 0.15. Weighted average common shares outstanding were 57,204,402, against 34,396,431.

For the nine months, net loss was USD 12.7 million, or USD 0.25 per share, against USD 15.7 million, or USD 0.48 per share. Research and Development expenses for the nine months decreased approximately USD 3.3 million, or 32%, while selling, general and administrative expenses increased approximately USD 0.7 million, or 12%.

Regulatory and Technology Developments

The company states its Credit card sized 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and its 12-Lead ECG synthesis software received FDA clearance in December 2025. In October 2026, it received FDA Breakthrough Designation for Heart Attack Assessment, which the filing states provides prioritized FDA interaction as the company advances toward a pivotal study and positions it to pursue an expedited Medicare coverage pathway.

Management said on its call that the designation also enrolled the company in the FDA's TAP program, which it said enables faster communication with the agency and opens discussions with the Centers for Medicare & Medicaid Services and payers on reimbursement and clinical trial needs. It outlined core priorities of heart attack detection, working with the FDA, reimbursement, AI-related initiatives and cost efficiency.

Going Concern, Financing and Listing

As of September 30, 2026, the company had cash and cash equivalents of approximately USD 6.1 million, against USD 4.4 million at the end of 2025. The filing states factors including its history of losses and negative cash flows from operations raise substantial doubt about its ability to continue as a going concern, and that it does not project material commercial revenue in 2026. It states continued operations depend on raising additional Capital through Equity or debt financings or strategic relationships.

On August 14, 2026, the company entered into an At-The-Market Equity Offering Sales Agreement with Titan Partners Securities LLC to sell up to USD 25,000,000 of common stock. No shares were issued under that agreement in the nine months ended September 30, 2026, although 970,467 shares were issued under an earlier at-the-market program for net proceeds of USD 1.5 million. Management said it raised approximately USD 4 million of net proceeds through the Facility since quarter end, and that it projects baseline fourth-quarter operating cash outflow below USD 2.5 million.

On the call, management also addressed a December 28 Nasdaq minimum bid compliance deadline, saying it is in communication with Nasdaq and in good standing, and referring to a further 180-day extension.